HC Wainwright Maintains Buy Rating on Nurix Therapeutics, Sets $36 Target
HC Wainwright maintained its Buy rating on Nurix Therapeutics and a $36.00 price target. The target implies 44.3% upside from the Oct. 15 close of $24.95.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.